134 related articles for article (PubMed ID: 21675910)
21. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
22. Newly recognized ocular side effects of erlotinib.
Methvin AB; Gausas RE
Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Vasile E; Tibaldi C; Chella A; Falcone A
J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary toxicity associated with erlotinib.
Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
[TBL] [Abstract][Full Text] [Related]
25. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH
Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379
[No Abstract] [Full Text] [Related]
26. Fulminant hepatic failure secondary to erlotinib.
Liu W; Makrauer FL; Qamar AA; Jänne PA; Odze RD
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):917-20. PubMed ID: 17625975
[TBL] [Abstract][Full Text] [Related]
27. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
28. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
[No Abstract] [Full Text] [Related]
29. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Siegel-Lakhai WS; Beijnen JH; Schellens JH
Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
[No Abstract] [Full Text] [Related]
32. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
33. Erlotinib: optimizing therapy with predictors of response?
Goodin S
Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
[No Abstract] [Full Text] [Related]
34. Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
Garfield D; Kashef G
Lung Cancer; 2006 Mar; 51(3):389-90. PubMed ID: 16359750
[No Abstract] [Full Text] [Related]
35. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
Langer CJ
J Clin Oncol; 2007 Mar; 25(7):751-3. PubMed ID: 17228017
[No Abstract] [Full Text] [Related]
36. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
[TBL] [Abstract][Full Text] [Related]
37. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib-associated alopecia in a lung cancer patient.
Costa DB; Kobayashi S; Schumer ST
J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
[No Abstract] [Full Text] [Related]
39. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Tsuboi M; Le Chevalier T
Med Oncol; 2006; 23(2):161-70. PubMed ID: 16720916
[TBL] [Abstract][Full Text] [Related]
40. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Qi WX; Sun YJ; Shen Z; Yao Y
J Chemother; 2015 Feb; 27(1):40-51. PubMed ID: 24724908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]